Medical Marijuana Is Not Regulated as Most Medicines Are

Another marijuana-based drug, nabiximol (Civicax), is available in Canada and several European countries to treat spasticity and nerve pain in patients with multiple sclerosis.

Medicinal cannabis is hardly a new therapeutic agent. It was widely used as a patented drug in the United States during the 19th and 20th centuries and was listed in the United States Pharmacopoeia until the passage of the Marijuana Tax Act in 1937.

Then in 1970 a federal law made it a Schedule 1 controlled substance, which restricted access to marijuana for legitimate research. Also complicating efforts to establish medical utility is that plants such as marijuana contain hundreds of active chemicals, the amount of which can vary from batch to batch. The findings regarding the benefits and risks are highly unreliable until researchers have studied the known quantities of pure substances.

Dr. Finn’s book states that, here are some conclusions by experts about the role of medical marijuana in their respective fields:

People who use marijuana for pain relief do not reduce their dependence on opioids. In fact, Drs. “Drug patients who use marijuana even for pain still report their pain levels to be 10 on a scale of 1 to 10,” Finn said. The author of the chapter on pain, Drs. Peter R. Wilson, a pain specialist at the Mayo Clinic in Rochester, Maine, and Dr. of the Greater Los Angeles VA Healthcare Service. Sanjog Pangarkar concluded, “Cannabis itself does not produce analgesia anymore. Paradoxically opioids can interfere with analgesia.” 2019 study of 450 adults in Journal of Addiction Medicine It was found that medical marijuana not only failed to relieve patients’ pain, but it increased the risk of anxiety, depression, and substance abuse.

Dr. Alan C. Neurologists at the Institute of Neurologists at Anglowood in Bowling, Klov, have noted that while marijuana has been widely studied as a treatment for multiple sclerosis, results from randomized clinical trials have been consistent. The tests showed some but limited effectiveness overall and in one of the largest and longest trials, placebo performed better in treating spasticity, pain, and bladder dysfunction, Drs. Bowling wrote. Most trials used pharmaceutical-grade cannabis that is not available in dispensaries.

Studies suggesting marijuana could reduce the risk of glaucoma dates back to the 1970s. In fact, THC exerts less pressure inside the eye, but in the form of DRS. Finn T., an ophthalmologist at the University of Oklahoma Health Sciences Center. John and Jean R. Hosier wrote, “To achieve therapeutic levels of marijuana in the bloodstream to treat glaucoma, a person must smoke approximately six to eight times a day.” The point at which the person focuses on focusing like work and driving and Will be unable to perform tasks requiring focus “The person will be physically and mentally incapable. Major eye care medical societies have put the thumbs down to treat cataracts.

Allison Karst, a psychiatric pharmacy specialist at the VA Tennessee Valley Healthcare System, who Reviewed the benefits and risks of medical marijuana, Concluded that marijuana “may have a negative impact on mental health and neurological function”, including worsening symptoms of PTSD and bipolar disorder.

Dr. Karst cited a study that said only 17 percent of edible cannabis products were accurately labeled. In an email she wrote that the lack of regulation “causes difficulty in destroying the evidence available for various products on the consumer market given the differences in consumer structure and purity.” He warned the public to weigh both the “potential benefits and risks” that I can join. Caviar emptier – Careful customer.

Source link

Leave a Comment